Artificial intelligence in nongynecologic cytology: A systematic review of current research and commercial tools
Cancer Cytopathology · 2026-04 · 134 (4)
DOI: 10.1002/cncy.70092 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Cytopathology, online erschienen am 20.03.2026. Verfasst von Tsandmaa Byambadorj und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Artificial Intelligence, Cytodiagnosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background
Nongynecologic (non‐GYN) cytology plays an important role in cellular and molecular cancer diagnosis, although its use is limited by variability and interobserver discrepancies. Recent studies suggest that artificial intelligence (AI) may improve diagnostic consistency and performance.
Methods
This systematic review evaluated contemporary AI research in non‐GYN cytology and examined commercially available systems. MEDLINE, Embase, and the Cochrane Library were searched for English‐language studies published from January 2010 to September 2024. Of ~24,000 records screened, 71 met inclusion criteria. Commercial platforms (KFBIO, Landing Med, VitaDx/VisioCyt, AIxMED, and CellsVision) were assessed using publicly available regulatory documents, technical specifications, and vendor‐reported validation data.
Results
Many studies reported high internal diagnostic performance, often exceeding 90% accuracy. Patch‐level performance often reached ~94%, exceeding whole slide image‐level metrics. Reduced interobserver variability was frequently observed, with accuracies of 95.9% for senior and 94.4% for junior pathologists. Several studies documented shorter diagnostic time. Thyroid (37%) and urinary bladder (30%) cytology were most frequently studied. AI applications included categorization, segmentation, and atypia detection, with recent work exploring immunocytochemistry support, mutation‐associated pattern recognition, and indirect prediction of histologic features.
Conclusion
AI in non‐GYN cytology shows promise but remains limited by data set quality, weak external validation, and regulatory barriers. At present, AI tools function primarily as decision‐support systems. Advancing clinical adoption will require multicenter validation, standardized data sets, and careful integration with expert interpretation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
ORCID-Profile: Tsandmaa Byambadorj
Förderung
- National Research Foundation of Korea
Zitieren
APA
Byambadorj, T., Alam, M. R., & Chong, Y. (2026). Artificial intelligence in nongynecologic cytology: A systematic review of current research and commercial tools. Cancer Cytopathology, 134(4). https://doi.org/10.1002/cncy.70092
Vancouver
Byambadorj T, Alam MR, Chong Y. Artificial intelligence in nongynecologic cytology: A systematic review of current research and commercial tools. Cancer Cytopathology. 2026;134(4). doi:10.1002/cncy.70092
BibTeX
@article{Byambadorj2026,
author = {Byambadorj, Tsandmaa and Alam, Mohammad Rizwan and Chong, Yosep},
title = {Artificial intelligence in nongynecologic cytology: A systematic review of current research and commercial tools},
journal = {Cancer Cytopathology},
year = {2026},
volume = {134},
number = {4},
doi = {10.1002/cncy.70092}
}
EUVIMED